Parenteral Drugs (India) Ltd

Know More
Stock not tradded

3.390.00 (0.00%)

04:01 PM,21st Aug 2023

BSE : 524689


Sector : Health care

ISIN Code : INE904D01019

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Aug 21 2023 | 04:01 PM IST

Market Cap (₹ Cr)


Turnover (₹ Cr)


Volume (Shares)

Face Value


52-WK High


52-WK High Date

13 Mar 2023

52-WK Low


52-WK Low Date

21 Aug 2023

All Time High


All Time High Date

11 Nov 2010

All Time Low


All Time Low Date

14 Oct 2019

Parenteral Drugs (India) Ltd

Parenteral Drugs (India) Ltd is an India-based pharmaceutical company. The company develops manufactures and markets a range of pharmaceutical products in India. Their products include solid and liquid orals such as antibiotics and anti-bacterial anti-ulcerant analgesics/anti-inflammatory multivitamins and minerals anxiolyic antiprotozoal anticold anthelmintic anti-histaminic muscle relaxant cardiac antidiabetic cough syrup appetite enhancer and injections. The company produces various therapeutic segments of In-Vitro (I V) Fluids such as electrolytes antibacterial energy replenisher irrigation solution osmotic diuretic dialysis solution. They also produce 400-milligram Ciprofloxacin infusion in 200 milliliter with 5% dextose. Apart from the single dose dispensers the company has also launched multi-dose eye/ ear drops in plastic containers. The dispensers are made using the form-fill-seal technology.Parenteral Drugs (India) Ltd was incorporated in the year 1983 as a private limited company. In the year 1989 the company established their first unit to manufacture I V Fluids in Polypropylene containers with a capacity of 18 lakh bottles per annum. In March 1994 the company was converted into a public limited company. In September 1994 the company came out with a public issue at a premium of Rs 80 aggregating Rs 7.03 crore to part-finance their Rs 8.97crore expansion. During the year 1994-95 the company set up a joint venture unit in Ukraine for manufacture of a wide range of pharmaceuticals. In addition they set up a unit for the manufacture of I V Fluids at Jalandhar in Punjab. During the year 1997-98 the company purchased 100% equity of the Parenteral Drugs International Ltd and made it a wholly owned subsidiary of the company. They also purchased 50% equity in Parental Drugs (Punjab) Ltd. During the year 1999-2000 the company was awarded ISO 9002 Certification as a symbol of quality products.During the year 2003-04 the company installed Injections with the production capacity of 516 lakh numbers. During the year 2005-06 the company increased the production capacity of I V Fluid Transfusion by 45000000 Nos to 120000000 Nos. In addition they set up a plant for manufacturing pharmaceutical products at Baddi in Himachal Pradesh. During the year 2006-07 the company increased the production capacity of Tablets/ Capsules by 1125000000 Nos Ampoules by 90000000 Nos and Injections 56400000 Nos. During the year 2007-08 they increased the production capacity of Large Volume by 30000000 Nos and Ampoules by 95000000 Nos.The Scheme of Amalgamation was sanctioned by the Hon'ble High Court of Judicature at Bombay vide its Order dated 12th October 2009. Under the scheme of amalgamation M/s. PFL Holdings Private Limited and M/s. Goa Holdings (India) Private Limited amalgamated with the Company and consequently M/s.Punjab Formulations Limited and M/s.Goa Formulations Limited became wholly-owned subsidiaries of the Company with effect from 1st November 2008.The Company incorporated a wholly-owned subsidiary in Kazakhstan in the name of Parenteral Drugs Kazakhstan to undertake the business of manufacturing of pharmaceutical products during 2008. In 2009 the Company launched products comprised of Falcistar and Merogol for Injections and tablets/ capsules like Azimist and Megastar. It launched the products under the oncology (anti-cancer) segment comprising of Fludapar Trexopar Mindro and Ifoparwith Mesna.During 2009-10 Company converted 1200000 warrants into equity shares of Rs. 10/-each which were issued by way of preferential allotment on 24th August 2009 which were allotted to M/s.Mahaganpati Investments Private Limited a Company under Promoter Category. During FY 2010-11 10 new products such as GRASIPAR PFS LEUCOPAR-50 INJECTION PACOFF EXPECTORANT PIDIMOL IV 5 FU-PAR INJECTION BOTEPAR INJECTION ERLOPAR TABLETS TEGNID INJECTION CEFACE CV TABLETS ERLOPAR TABLETS ANTOXY-2 SYRUP and TAMOLGAN IV were introduced in the market.In 2014 Punjab Formulations Limited a wholly owned subsidiary ceased to be in existence as the said Company was amalgamated with Infutec Healthcare Limited (Formerly: Goa Formulations Limited) a wholly owned subsidiary of the Company w.e.f. 12 September 2014 vide Order of the Honorable High Court of Bombay Judicature.During year 2015-16 Company disinvested equity investment in two subsidiary companies namely Parentech Healthcare Limited and Parenteral Surgicals Limited. During 2016-2017 the Company disinvested from the equity shares held in its 2 subsidiary companies namely Abhay Drugs Limited and Anjaney Pharmaceuticals Limited. During the year 2018-19 Infutec Healthcare Limited an erstwhile wholly owned subsidiary ceased to be a subsidiary of company w.e.f 10 July 2018.

Parenteral Drugs (India) Ltd - Key Fundamentals

Market Cap (₹ Cr)


EPS - TTM (₹) [S]


P/E Ratio (X) [S]


Face Value (₹) 10
Latest Dividend (%)20.00
Latest Dividend Date 13 Sep 2010
Dividend Yield (%) -
Book Value Share (₹) [S]-300.60
P/B Ratio (₹) [S]-0.01
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
DSP Midcap Fund (G) 2.85 146927 0.26

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High



Week Low/High



Month Low/High



Year Low/High



All time Low/High



Share Price Returns

1 Week%%0.910.75%
1 Month%%2.392.40%
3 Month%%9.3710.41%
6 Month%%12.8815.14%
1 Year%%25.2929.19%
3 Year%%46.7450.00%

Company Info

Company Information

Chairman : Manoharlal Gupta

Whole-time Director : Govind Das Garg

Independent Director : Dharam Pal Khanna

Independent Director : Dilip Kumar Sinha

Non Executive Director : Anil Mittal

Independent Director : Manish Verma

Managing Director & CFO : Vinod Kumar Gupta

Independent Director : Deepali Garhewal

Independent Director : Chhaya Gupta

Registered Office: 340 Laxmi Plaza Laxmi Indl Est, New Link Road Andheri (West),Mumbai,Maharashtra-400053 Ph: 91-022-61725900-1